Salvia Investment GmbH / Helmut Wolfgang Jeggle puts $6.0m into Bambusa Therapeutics Bambusa Therapeutics, Inc. · NASDAQ: BBTX
- What they did
- On 2 November 2026, Salvia Investment GmbH (Holzkirchen, Bavaria), of which Helmut Wolfgang Jeggle is the principal and a Bambusa director, reported transaction code P for 375,000 shares at exactly $16.00, total $6,000,000. The same Form 4 reports code C: 4,769,701 preferred shares converting one-for-one into common “prior to the closing of the Issuer’s initial public offering.” Holdings after: 9,264,301 shares, direct.
- The document
- Form 4, Bambusa Therapeutics, filed 2 Nov 2026 (SEC CIK 2044950); prospectus 424B4 dated 29 Oct 2026.
Consensus read
A $6m open-market insider purchase by the company’s largest shareholder, three days after listing. The wires carried it exactly that way: “director adds $6M of BBTX stock.” A pre-IPO backer who already owns 22% and still writes a fresh cheque at the offer price is making about as unambiguous a statement of confidence in the bispecific platform as the disclosure regime permits.
Contrarian read
This is not a purchase in any informational sense. It is participation in Bambusa’s own primary offering at the offer price on the closing date — and it is participation at a size that failed to defend the position. Jeggle spent $6m and ended the week owning a smaller share of the company than he owned before it. The signal content is roughly zero, and the direction, if anything, is the opposite of the headline.
Evidence that discriminates
- The price has no decimals. Exactly $16.00, which is the IPO price per the 424B4. Open-market execution of 375,000 shares produces a weighted-average price with four decimal places and a footnoted range — compare LOR’s $34.5864 and Lonegro’s $142.9238 in this same edition. A flat round price is a primary-market print, not a market print.
- Same form, same date, as the preferred conversion. The code C conversion is footnoted as occurring immediately before the IPO closing. The code P sits on the identical 2 Nov date. An Oct 29 pricing settles T+2 into 2 November. The two events are one event.
- The arithmetic kills the conviction read outright. Pre-IPO: 8,889,301 of 40,386,875 shares = 22.0%. Post-IPO: 9,264,301 of the 50,942,430 shares the prospectus states will be outstanding = 18.2%. He bought, and his ownership fell by 3.8 points.
Inference, labelled as such: the 375,000 figure sits just above the ~369,444 shares (3.5% of the deal) the prospectus reserves for directors, officers and related persons. The filing does not say the purchase came through that programme and I could not confirm it. Treat as a live possibility, not a finding.
What would falsify me
A footnote or amended Form 4 showing the 375,000 shares were bought on Nasdaq across a price range rather than at the offer; or a subsequent Form 4 in November showing Salvia buying in the open market at prices away from $16.00. Either would make this a real purchase decision and my read wrong.
PatternThe prospectus lists ATHOS — the Strüngmann family office Jeggle formerly ran — among existing significant holders alongside Salvia and RA Capital. Jeggle’s pattern is early private positions carried into listings, not open-market accumulation after them. Nothing here departs from it.